Lastacaft Once Daily Relief (alcaftadine)
Ophthalmic Antiallergic Agents Ophthalmic (Eye) Drops
Last reviewed · Source: First Databank (FDB) drug data
Overview
Alcaftadine is a histamine H1-receptor antagonist.
Alcaftadine is a histamine H1-receptor antagonist. The drug inhibits the release of mediators (e.g., histamine) from cells involved in hypersensitivity reactions (e.g., mast cells) and decreases chemotaxis and activation of eosinophils.
Alcaftadine appears rapidly in the systemic circulation following topical application to the eye. Peak plasma concentrations of the drug and its active carboxylic acid metabolite occur at a median of 15 minutes and at 1 hour, respectively, following administration of alcaftadine ophthalmic solution, and plasma concentrations fall to below the limit of quantitation by 3 and 12 hours, respectively, following administration. Metabolism of alcaftadine to its active carboxylic acid metabolite is mediated by cytosolic enzymes; data for orally administered alcaftadine indicate that the carboxylic acid metabolite is eliminated mainly in urine.
Alcaftadine is not metabolized by the cytochrome P-450 (CYP) enzyme system; neither alcaftadine nor its carboxylic acid metabolite substantially inhibits major CYP enzymes in vitro.
USES: This medication is used to prevent itching of the eyes due to allergies. Alcaftadine is an antihistamine. It works by blocking a certain natural substance (histamine) that causes allergic symptoms.
Do not use this medication to treat red or irritated eyes due to wearing contact lenses. Contact your doctor for further instructions if this occurs.
Generic name: alcaftadine
Pronunciation: (al-KAF-ta-deen)
Drug class: Ophthalmic Antiallergic Agents
Therapeutic class: Ophthalmic Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Lastacaft Once Daily Relief
Indications
The following indications are listed for Lastacaft Once Daily Relief:
- Allergic Conjunctivitis
Also known as: Allergy Eye Itch, Atopic Conjunctivitis, Itchy Eyes Due To Allergies, Ocular Itching Due To Allergies.
Dosing
No dosing information is available for this tab.
Alcaftadine is applied topically to the eye as an ophthalmic solution. The ophthalmic solution is for topical ophthalmic use only. Care should be taken to avoid contamination of the solution container.
Alcaftadine ophthalmic solution contains benzalkonium chloride, which may be absorbed by some soft contact lenses. Patients should be advised to remove their contact lenses prior to administration of each dose of alcaftadine ophthalmic solution. Patients whose eyes are not red may reinsert soft contact lenses after 10 minutes following administration of the ophthalmic solution.
Alcaftadine ophthalmic solution is for topical ophthalmic use only. The ophthalmic solution should not be instilled while the patient is wearing contact lenses. Patients should be advised not to wear contact lenses if their eyes are red. The ophthalmic solution should not be used to treat contact lens-related irritation. (See Dosage and Administration: Administration.)
| Drug label | Dosing type | Instructions |
|---|---|---|
| Lastacaft Once Daily 0.25% Drp | Maintenance | Instill 1 drop into affected eye(s) by ophthalmic route once daily. |
| Drug label | Dosing type | Instructions |
|---|---|---|
| Alcaftadine 0.25% Eye Drop | Maintenance | Instill 1 drop into affected eye(s) by ophthalmic route once daily. |
Drug interactions
No formal drug interaction studies have been performed to date.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
The manufacturer states that there are no known contraindications to the use of alcaftadine.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
- No disease contraindications
Adverse reactions
The most common adverse ocular effects (reported in less than 4% of eyes treated with alcaftadine ophthalmic solution) include irritation, burning, and/or stinging upon instillation; redness; and pruritus. Common nonocular adverse effects (reported in less than 3% of patients receiving the drug) include nasopharyngitis, headache, and influenza.
There are no severe adverse reactions for this drug.
More Frequent
- Ocular irritation
Less Frequent
- Headache disorder
- Ocular itching
- Ocular redness
- Pharyngitis
Rare or Very Rare
- Allergic dermatitis
- Blurred vision
- Drowsy
- Eye tearing
- Eyelid edema
- Eyelid erythema
- Facial edema
- Ocular discharge
- Periorbital edema
Precautions
No enhanced messaging available.
Safety and efficacy of alcaftadine ophthalmic solution have not been established in children younger than 2 years of age. Pediatric patients 10 years of age or older were included in controlled clinical trials evaluating efficacy and safety of alcaftadine ophthalmic solution, and pediatric patients 3 years of age or older were included in environmental studies establishing safety of the drug. Efficacy of the drug in children 2-9 years of age was extrapolated from demonstrated efficacy in older children and adults.
Category B. (See Users Guide.)
It is not known whether alcaftadine is distributed into milk following topical application to the eye. Because many drugs are distributed into milk, caution should be exercised when alcaftadine is used in nursing women.
No overall differences in safety or efficacy were observed between geriatric patients and younger patients.
ICD codes
| Code | Type | Description |
|---|---|---|
| Allergic conjunctivitis | ||
| H10.1 | ICD10CM | Acute atopic conjunctivitis |
| H10.10 | ICD10CM | Acute atopic conjunctivitis, unspecified eye |
| H10.11 | ICD10CM | Acute atopic conjunctivitis, right eye |
| H10.12 | ICD10CM | Acute atopic conjunctivitis, left eye |
| H10.13 | ICD10CM | Acute atopic conjunctivitis, bilateral |
| H10.44 | ICD10CM | Vernal conjunctivitis |
| H10.45 | ICD10CM | Other chronic allergic conjunctivitis |
| H16.26 | ICD10CM | Vernal keratoconjunctivitis, with limbar and corneal involvement |
| H16.261 | ICD10CM | Vernal keratoconjunctivitis, with limbar and corneal involvement, right eye |
| H16.262 | ICD10CM | Vernal keratoconjunctivitis, with limbar and corneal involvement, left eye |
| H16.263 | ICD10CM | Vernal keratoconjunctivitis, with limbar and corneal involvement, bilateral |
| H16.269 | ICD10CM | Vernal keratoconjunctivitis, with limbar and corneal involvement, unspecified eye |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.